Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis

Date

21 Oct 2023

Session

Poster session 11

Topics

Cancer Biology;  Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Thomas Aparicio

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

T. Aparicio1, J. Henriques2, M. Svrcek3, A. Zaanan4, S. Manfredi5, A. Casadei Gardini6, D. Tougeron7, J. Gornet8, D. Pezet9, E. terrebonne10, G. Piessen11, P. Afchain12, C. Lecaille13, M. Pocard14, T. Lecomte15, V. Burgio16, F. Di Fiore17, S. Cascinu18, D. Vernerey19, P. Laurent puig20

Author affiliations

  • 1 Gastroenterology And Digestive Oncology Department, Hopital Saint Louis AP-HP, 75010 - Paris/FR
  • 2 (2) methodology And Quality Of Life Unit In Oncology, Ea 3181, CHU Besançon, Hôpital Jean Minjoz, 25000 - Besançon/FR
  • 3 Pathology, Hopital Saint-Antoine, 75012 - Paris/FR
  • 4 Gastroenterology And Digestive Oncology Department, Hopital Europeen Georges-Pompidou - AP-HP, 75015 - Paris/FR
  • 5 Gastroenterology And Digestive Oncology Department, CHU Dijon, 21000 - Dijon/FR
  • 6 Medical Oncology Department, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 7 Gastroenterology, CHU Poitiers - Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 8 Gastroenterology, Hopital Saint Louis AP-HP, 75010 - Paris/FR
  • 9 Surgery, CHU Estaing, 63003 - Clermont-Ferrand/FR
  • 10 Gastroenterology, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 11 Surgery, C.H.U. Claude Huriez, 59037 - Lille/FR
  • 12 Oncology, Hôpital Saint-Antoine, 75571 - Paris/FR
  • 13 Gastroenterology, POLYCLINIQUE BORDEAUX NORD AQUITAINE, 33300 - Bordeaux/FR
  • 14 Surgery, Hopital Pitié Salpetrière AP-HP, 75013 - Paris/FR
  • 15 Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 16 Oncology, AOU Mater Domini - Policlinico Universitario Germaneto, 88100 - Catanzaro/IT
  • 17 Gastroenterology, CHU de Rouen Normandie, 76000 - Rouen/FR
  • 18 Oncology Dept., Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 19 Medical Oncology Department, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besancon/FR
  • 20 Genetic, Paris Descartes University, 75006 - Paris/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 650P

Background

Several genomic alterations have been described in small bowel adenocarcinoma (SBA) but the prognostic value of these alterations remains unclear. The aim of this multicentre study was to determine the genomic profile of SBA and its impact on the prognosis.

Methods

Three cohorts in France and Italy were pooled. A common dataset of genomic analysis have been performed on 35 genes of interest. MSI (MicroSatellite Instable) and MMR (MisMatch Repair) status were also assessed.

Results

A total of 188 tumour samples had conclusive results for mutation analysis. The patients (pts) were male (55.3%), with duodenum primary (58.5%), stage I-II (39.6%), III (40.6%) and IV (18.8%). with a predisposing disease (21%) mainly Lynch syndrome (LS) (n=19) and Crohn disease (CD) (n=11). The most frequent mutation were KRAS (42.0%) of which 7/79 G12C, TP53 (40.4%), APC (19.1%), PIK3CA (18.6%), SMAD4 (12.8%) and ERBB2 (9.6%). TP53 mutations were more frequent in CD (81.8%) but less frequent in LS (15.8%) than in no predisposing disease (39%). ERBB2 mutations were more frequent in LS (26.3%) than in no predisposing disease (7.5%). No APC mutation was observed in CD. KRAS and SMAD4 mutations were more frequent in tumour than in localized tumour (59.4% vs 37.7%, p=0.0164) and (24.3% vs 9.9%, p=0.0187). ERBB2 mutations were less frequent in metastatic than in localized tumour (0% vs 11.9%, p=0.0272). For localized tumour univariate analysis revealed that: age ≥65 (p=0.0327), T4 (p=0.570), high grade (p=0.0028) stage III (p=0.0390) and wild type APC (p=0.395) were associated with a poor overall survival (OS). In multivariate analysis: high grade (p=0.023), age ≥65 (p=0.0123) and wild type APC (p=0.0254) were associated with a poor OS. For metastatic tumour a trend for a better OS was observed in case of a mutated KRAS tumour (HR=0.6 (0.34-1.06), p=0.0797) in univariate analysis. dMMR/MSI status was available in 238 pts. Overall, dMMR/MSI was reported in 29.8%, 31.8% in localized and 11.3% in metastatic tumour. dMMR/MSI was associated with a better OS (HR=0.61 [0.39-0.96], p=0.0333).

Conclusions

There is different genomic profile according to the predisposing disease. MSI/dMMR predict a better prognosis. APC mutation in localized and KRAS mutation in metastatic tumour are associate with a better prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Fondation ARCAD, Programme Hospitalier de Recherche Clinique.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.